June 27, 2006

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

21

June 27, 2006

10/653,776

September 3, 2003

544/281  

C07D   487/04   (20060101)  

This application claims benefit of priority from U.S. provisional patent application Ser. No. 60/408,029 filed Sep. 4, 2002.

514/259.31   544/281  

7514442 - Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors - Owned by Schering Corporation (Kenilworth, NJ) Pharmacopeia, Inc. (Cranbury, NJ) In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.